Generate Biomedicines, Inc. is a clinical-stage biotechnology company that leverages artificial intelligence and machine learning to design novel protein therapeutics. Headquartered in Massachusetts, the company utilizes a proprietary generative biology platform that integrates computational design with high-throughput laboratory experimentation. Its lead clinical candidate, GB-0895, is a long-acting anti-TSLP monoclonal antibody in Phase 3 trials for severe asthma and Phase 1b for chronic obstructive pulmonary disease (COPD). The company's oncology pipeline includes GB-4362, an MMAE payload neutralizer, and GB-5267, a CAR-T cell therapy targeting ovarian cancer. In addition to advancing its internal pipeline, Generate Biomedicines engages in strategic, multi-target drug discovery collaborations with major pharmaceutical companies such as Amgen and Novartis.
